Lazard Asset Management LLC reduced its position in Certara, Inc. (NASDAQ:CERT – Free Report) by 69.1% in the 1st quarter, HoldingsChannel.com reports. The firm owned 135,234 shares of the company’s stock after selling 302,533 shares during the period. Lazard Asset Management LLC’s holdings in Certara were worth $771,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors have also recently bought and sold shares of CERT. AQR Capital Management LLC acquired a new stake in Certara in the first quarter valued at $259,000. Goldman Sachs Group Inc. increased its position in shares of Certara by 65.6% in the first quarter. Goldman Sachs Group Inc. now owns 228,996 shares of the company’s stock valued at $2,267,000 after buying an additional 90,724 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in shares of Certara by 13.6% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 299,528 shares of the company’s stock worth $2,965,000 after buying an additional 35,954 shares during the last quarter. Jane Street Group LLC raised its stake in shares of Certara by 17.1% during the 1st quarter. Jane Street Group LLC now owns 277,054 shares of the company’s stock worth $2,743,000 after buying an additional 40,463 shares during the last quarter. Finally, JPMorgan Chase & Co. boosted its position in shares of Certara by 29.3% in the 2nd quarter. JPMorgan Chase & Co. now owns 93,057 shares of the company’s stock worth $1,089,000 after buying an additional 21,099 shares in the last quarter. 73.96% of the stock is owned by institutional investors and hedge funds.
Certara Stock Up 2.7%
CERT opened at $8.01 on Thursday. The firm has a market cap of $1.25 billion, a P/E ratio of -17.80 and a beta of 1.44. The business’s fifty day simple moving average is $6.47 and its 200 day simple moving average is $6.55. Certara, Inc. has a 52 week low of $4.45 and a 52 week high of $13.88. The company has a quick ratio of 1.88, a current ratio of 2.55 and a debt-to-equity ratio of 0.30.
Analyst Upgrades and Downgrades
A number of equities research analysts recently commented on CERT shares. Barclays increased their price objective on shares of Certara from $6.50 to $7.50 and gave the company an “equal weight” rating in a research note on Wednesday. BMO Capital Markets reduced their price target on shares of Certara from $7.00 to $6.00 and set a “market perform” rating on the stock in a report on Tuesday, May 12th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Certara in a research report on Friday, May 29th. KeyCorp dropped their price objective on shares of Certara from $10.00 to $8.00 and set an “overweight” rating for the company in a research note on Monday, April 13th. Finally, Robert W. Baird dropped their price objective on shares of Certara from $7.00 to $6.00 and set a “neutral” rating for the company in a research note on Tuesday, May 12th. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $8.95.
Read Our Latest Analysis on CERT
More Certara News
Here are the key news stories impacting Certara this week:
- Positive Sentiment: Certara completed its previously authorized $100 million share-repurchase program, and its board approved an additional $50 million for buybacks. The expanded repurchase authorization may support earnings per share and signal management confidence in the stock. Certara Reports Second Quarter 2026 Financial Results
- Positive Sentiment: Management reaffirmed its 2026 revenue guidance. The earnings discussion also highlighted relative strength in Certara’s software business, which helped offset pressure in its services operations. Certara Earnings Call: Software Strength Amid Services Strain
- Neutral Sentiment: Certara appointed Julien Perrier as chief commercial officer, representing a leadership transition in a role important to sales execution and growth. The longer-term effect will depend on whether the change improves commercial momentum. Certara Announces Leadership Change in Commercial Executive Role
- Negative Sentiment: Second-quarter revenue was $93.27 million, below the $98.09 million consensus and down 10.8% year over year. Adjusted earnings of $0.08 per share also missed estimates of approximately $0.09 to $0.10, although EPS improved from $0.07 a year earlier. Certara Q2 Earnings and Revenues Lag Estimates
- Negative Sentiment: Barclays raised its price target from $6.50 to $7.50 but retained an equal-weight rating, implying analysts see limited upside after the recent rebound. Barclinga analyst action
About Certara
Certara is a biosimulation software and services company that partners with pharmaceutical, biotechnology and medical device developers to accelerate drug discovery, development and regulatory approval. The company’s platform integrates quantitative pharmacology, real-world evidence, artificial intelligence and machine learning to model and simulate drug behavior across a range of therapeutic areas and patient populations. By applying these mechanistic and data-driven approaches, Certara helps its clients predict clinical outcomes, optimize dosing strategies and streamline decision-making throughout the product lifecycle.
The company’s offerings are divided into software tools and consulting services.
Featured Stories
- Five stocks we like better than Certara
- SpaceX: Love the Company, But the Stock Is a Harder Call
- Ulta’s Growth Is Real, But So Are the Risks
- BWX Technologies Is Turning the AI Power Problem Into a Nuclear Growth Story
- Meta’s Earnings Drop Shows Wall Street Wants More Than Ad Growth
Want to see what other hedge funds are holding CERT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Certara, Inc. (NASDAQ:CERT – Free Report).
Receive News & Ratings for Certara Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Certara and related companies with MarketBeat.com's FREE daily email newsletter.
